An evaluation of the available pharmacotherapy for the treatment of hirsutism

References

• Rashidi M, Sinclair R. Diagnosis and treatments of hirsutism: where are we? Expert Rev Dermatol. 2011;6:423–429.
   Google Scholar
• Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev. 2000;21:347–362.
   PubMed Web of Science ®Google Scholar
• Messenger AG, De Berker DAR, Sinclair RD, et al. (2010). Disorders of Hair Rook's Textbook of Dermatology. Oxford: Wiley-Blackwell.pp. 66.70–66.71.
   Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. The evaluation and treatment of androgen excess. Fertil Steril. 2006;86:S241–7.
   PubMedGoogle Scholar
• Keegan A, Liao L-M, Boyle M. ‘Hirsutism’: a psychological analysis. J Health Psychol. 2003;8:327–345.
   PubMed Web of Science ®Google Scholar
• Pasch L, He SY, Huddleston H, et al. Clinician vs self-ratings of hirsutism in patients with polycystic ovarian syndrome: associations with quality of life and depression. JAMA Dermatol. 2016;152:783–788. .
   PubMedGoogle Scholar
• Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the androgen excess and polycystic ovary syndrome society. Hum Reprod Update. 2012;18:146–170.
   PubMed Web of Science ®Google Scholar
• Grabe S, Ward LM, Hyde JS. The role of the media in body image concerns among women: a meta-analysis of experimental and correlational studies. Psychol Bull. 2008;134:460–476.
   PubMed Web of Science ®Google Scholar
• Cook H, Brennan K, Azziz R. Reanalyzing the modified Ferriman-Gallwey score: is there a simpler method for assessing the extent of hirsutism? Fertil Steril. 2011;96:1266–70.e1.**. doi: 10.1016/j.fertnstert.2011.08.022.
   PubMedGoogle Scholar
• Somani N, Harrison S, Bergfeld WF. The clinical evaluation of hirsutism. Dermatol Ther. 2008;21:376–391.
   PubMed Web of Science ®Google Scholar
• van Zuuren Ej, Fedorowicz Z, Carter B. Interventions for hirsutism excluding laser and photoepilation therapy. Cochrane Database Syst Rev. 2013. DOI:10.1002/14651858.cd010334
   Google Scholar
• DeUgarte CM, Woods KS, Bartolucci AA, et al. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab. 2006;91:1345–1350. doi: 10.1210/jc.2004-2301.
   PubMed Web of Science ®Google Scholar
• Blume-Peytavi U. An overview of unwanted female hair. Br J Dermatol. 2011;165:19–23.
   PubMedGoogle Scholar
• Messenger AG, de Berker DA, Sinclair RD. Disorders of hair. In: Burns T, Breathnach S, Cox N Griffiths C, editors. Dermatology. 8th ed. (UK): Wiley-Blackwell.
   Google Scholar
• Young R, Sinclair RH II. Treatment. Australas J Dermatol. 1998;39:151–157.
   PubMedGoogle Scholar
• Sinclair R, Green J. Skin manifestations of polycystic ovary syndrome. In: Gabor T. Kovacs, Robert Norman, editors. Polycystic Ovary Syndrome. Cambridge University Press; 2007. p. 102–120.
   Google Scholar
• Shah D, Patel S. Hirsutism. Gynecological Endocrinol. 2009;25:140–148.
   PubMed Web of Science ®Google Scholar
• Paparodis R, Dunaif A. The Hirsute woman: challenges in evaluation and management. Endocr Pract. 2011;17:807–818.
   PubMed Web of Science ®Google Scholar
• Azziz R. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism: a prospective randomized study. J Clin Endocrinol Metab. 1995;80:3406–3411.
   PubMed Web of Science ®Google Scholar
• Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89:453–462.
   PubMed Web of Science ®Google Scholar
• Mazza A, Fruci B, Guzzi P, et al. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutr Metab Cardiovasc Dis. 2014;24:132–139.
   PubMed Web of Science ®Google Scholar
• Azadi-Yazdi M, Karimi-Zarchi M, Salehi-Abargouei A, et al. Effects of dietary approach to stop hypertension diet on androgens, antioxidant status and body composition in overweight and obese women with polycystic ovary syndrome: a randomised controlled trial. J Hum Nutr Diet. 2017;30(3):275–283. DOI:10.1111/jhn.12433
   PubMedGoogle Scholar
• TRE-SPCW G. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47.
   PubMedGoogle Scholar
• Teede HJ, Hutchison S, Zoungas S, et al. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine. 2006;30:45–53.
   PubMed Web of Science ®Google Scholar
• Blume-Peytavi U. How to diagnose and treat medically women with excessive hair. Dermatol Clin. 2013;31(1):57–65.
   PubMedGoogle Scholar
• Kaltsas GA, Isidori AM, Kola BP, et al. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab. 2003;88:2634–2643.
   PubMed Web of Science ®Google Scholar
• Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:1105–1120.
   PubMed Web of Science ®Google Scholar
• Blume-Peytavi U, Atkin S, Shapiro J, et al. European Consensus on the evaluation of women presenting with excessive hair growth. Eur J Dermatol. 2009;19:597–602.**. .
   PubMedGoogle Scholar
• Dessinioti C, Katsambas AD. Hirsutism and Hypertrichosis. In: Katsambas A, Lotti T, Dessinioti C D’Erme A, editors. European Handbook of Dermatological Treatments. Berlin Heidelberg: Springer; 2015. p. 385–396.
   Google Scholar
• Jacobsen S, Lauszus FF. Androgen-secreting tumours of the ovaries. Ugeskr Laeger. 2019;181(URL). https://europepmc.org/article/med/30729915.
   PubMedGoogle Scholar
• Hafsi W, Badri T Hirsutism [WWW Document]. https://europepmc.org/books/nbk470417 [cited 24 Feb 2023].
   Google Scholar
• Asfour L, Rutkowski D, Harries M. Drug-Induced Hair Changes. In: Lee H Creamer D, editors. Drug Eruptions. Cham: Springer International Publishing; 2022. p. 237–246.
   Google Scholar
• Haedersdal M, Gøtzsche PC. Laser and photoepilation for unwanted hair growth. Cochrane Database Syst Rev. 2006; CD004684. doi:10.1002/14651858.CD004684.pub2.
   PubMedGoogle Scholar
• van Zuuren Ej, Fedorowicz Z, Carter B, et al. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015; CD010334. doi:10.1002/14651858.CD010334.pub2.
   Google Scholar
• Barrionuevo P, Nabhan M, Altayar O, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2018;103:1258–1264. .
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Bersi C, Parrini D, et al. Treatment of hirsutism: comparisons between different antiandrogens with central and peripheral effects. Fertil Sterility. 1999;71:445–451.
   PubMed Web of Science ®Google Scholar
• der Spuy Zm V, le Roux Pa, Le Roux PA, et al., Cyproterone acetate for hirsutism. Cochrane Database Syst Rev. 2010: CD001125. 2003; 10.1002/14651858.CD001125.
   Google Scholar
• Champeaux-Depond C, Weller J, Froelich S, et al. Cyproterone acetate and meningioma: a nationwide-wide population-based study. J Neurooncol. 2021;151:331–338.
   PubMed Web of Science ®Google Scholar
• Lee KS, Zhang JJY, Kirollos R, et al. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas. Sci Rep. 2022;12(1):1942. DOI:10.1038/s41598-022-05773-z
   PubMedGoogle Scholar
• Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril. 2003;79:942–946.
   PubMed Web of Science ®Google Scholar
• Ahmad J, Shukla N, Khan AR, et al. Comparison of metabolic effects of metformin and rosiglitazone in the management of polycystic ovary syndrome (PCOS): a prospective, parallel, randomized, open-label study. Diabet Metab Syndrome: Clin Res Rev. 2008;2:37–46.
   Google Scholar
• Du Q, Wang Y-J, Yang S, et al. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin. 2012;28:723–730.
   PubMed Web of Science ®Google Scholar
• Sachdeva S. Hirsutism: evaluation and treatment. Indian J Dermatol. 2010;55:3–7.
   PubMedGoogle Scholar
• Vissing AC, Taudorf EH, Haak CS, et al. Adjuvant eflornithine to maintain IPL-induced hair reduction in women with facial hirsutism: a randomized controlled trial. J Eur Acad Dermatol Venereol. 2016;30:314–319.
   PubMedGoogle Scholar
• Ciotta L, Cianci A, Giuffrida G, et al. Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease. Fertil Steril. 1996;65:61–67.
   PubMed Web of Science ®Google Scholar
• Sagsveen M, Farmer JE, Prentice A, et al. Gonadotropin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003;CD001297. DOI:10.1002/14651858.CD001297
   PubMedGoogle Scholar
• Santhosh P, George M. Clascoterone: a new topical anti-androgen for acne management. Int J Dermatol. 2021;60:1561–1565.
   PubMedGoogle Scholar
• Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1233–1257.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Freiman JP, Tourtelot JB, et al. 3rd. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med. 1993;118:860–864.
   PubMed Web of Science ®Google Scholar
• Ibáñez L, Jaramillo A, Ferrer A, et al. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod. 2005;20:1833–1836.
   PubMed Web of Science ®Google Scholar
• Generali JA, Cada DJ. Flutamide: hirsutism in women. Hosp Pharm. 2014;49:517–520.
   PubMedGoogle Scholar
• Müderris B II, F OB, Güven M. New alternative treatment in hirsutism: bicalutamide 25 mg/day. Gynecol Endocrinol. 2002;16:63–66.
   PubMed Web of Science ®Google Scholar
• Moretti C, Guccione L, Di Giacinto P, et al. Combined oral contraception and bicalutamide in polycystic ovary syndrome and severe hirsutism: a double-blind randomized controlled trial. J Clin Endocrinol Metab. 2018;103:824–838.
   PubMed Web of Science ®Google Scholar
• Ismail FF, Meah N, Trindade de Carvalho L, et al. Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients. J Am Acad Dermatol. 2020;83:1478–1479.
   PubMed Web of Science ®Google Scholar
• Townsend KA, Marlowe KF. Relative safety and efficacy of finasteride for treatment of hirsutism. Ann Pharmacother. 2004;38:1070–1073.
   PubMed Web of Science ®Google Scholar
• Kim M-W, Park H-S, Park JS, et al. Five-alpha reductase inhibitor and breast cancer risk in men: a systematic review. Ann Dermatol. 2017;29:525–528.
   PubMedGoogle Scholar
• Zhou Z, Song S, Gao Z, et al. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019;14:399–406.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecological Endocrinol. 2015;31(7):501–505.
   PubMed Web of Science ®Google Scholar
• Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003;7:151–159.
   PubMedGoogle Scholar
• Benelli E, Del Ghianda S, Di Cosmo C, et al. a combined therapy with myo-inositol and d-chiro-inositol improves endocrine parameters and insulin resistance in pcos young overweight women. Int J Endocrinol. 2016;2016:3204083.
   PubMed Web of Science ®Google Scholar
• Lolou V. The role of probiotics and synbiotics on hirsutism. Fermentation. 2021;7:10.
   Google Scholar
• Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (Dogma)–a novel theory for the development of polycystic ovarian syndrome. Med Hypotheses. 2012;79:104–112.
   PubMed Web of Science ®Google Scholar
• Karamali M, Eghbalpour S, Rajabi S. Effects of probiotic supplementation on hormonal profiles, biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Arch Iran Med. 2018;21:1–7. URL. http://www.aimjournal.ir/Abstract/aim-1912
   PubMed Web of Science ®Google Scholar
• Maktabi M, Chamani M, Asemi Z. The effects of vitamin D supplementation on metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Horm Metab Res. 2017;49:493–498.
   PubMed Web of Science ®Google Scholar
• Nanni CA, Alster TS. Laser-assisted hair removal: side effects of Q-switched Nd: yAG, long-pulsed ruby, and alexandrite lasers. J Am Acad Dermatol. 1999;41:165–171.
   PubMed Web of Science ®Google Scholar
• Agrawal NK. Management of hirsutism. Indian J Endocrinol Metab. 2013;17:S77–82.
   PubMedGoogle Scholar
• Ekman P. A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia. Drug Saf. 1998;18:161–170.
   PubMedGoogle Scholar
• Kjærulff TM, Ersbøll AK, Green A, et al. Finasteride use and risk of male breast cancer: a case-control study using individual-level registry data from Denmark, Finland, and Sweden. Cancer Epidemiol Biomarkers Prev. 2019;28:980–986.
   PubMedGoogle Scholar
• Mackenzie IS, Macdonald TM, Thompson A, et al. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ. 2012;345:e4447.
   PubMedGoogle Scholar
• Hirschberg AL. Female hyperandrogenism and elite sport. Endocr Connect. 2020;9:R81–92.
   PubMedGoogle Scholar
• La Vignera S, Condorelli RA, Cannarella R, et al. Sport, doping and female fertility. Reprod Biol Endocrinol. 2018;16:108.
   PubMedGoogle Scholar
• Storer TW, Miciek R, Travison TG. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl. 2012;14:204–221.
   PubMedGoogle Scholar